Specialised Services clinical commissioning policies and service specification - 12th Wave

Overview

NHS England has today (29 April 2016) launched a 30 day public consultation on a proposed number of new products for specialised services, (including service specifications and clinical commissioning policies). There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicans and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the specifications and policies to date. Please note this is one of several public consultations on a proposed number of new draft products for specialised services. We now wish to test them further with wider groups of stakeholders.

Related documents

Clinical Commissioning Policies
 

Rituximab for the treatment of Primary Sjogren’s Syndrome (PSS) in adults (A13X03):

• Policy proposition
• Evidence review
• Clinical panel report
• Engagement report
• Impact assessment

Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) (A14X01):

• Policy proposition
• Evidence review
• Clinical panel report
• Engagement report
• Impact assessment